ReviewGenes & development2013
Chromatin targeting drugs in cancer and immunity.
Review in Genes & development, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Targeting lysine acetylation readers and writers.Nature reviews. Drug discovery · 2025Review
- Bromodomain inhibitors and therapeutic applications.Current opinion in chemical biology · 2023Review
- Evaluation of the Small-molecule BRD4 Degrader CFT-2718 in Small-cell Lung Cancer and Pancreatic Cancer Models.Molecular cancer therapeutics · 2021Article
- Structure-Based Screening of Tetrazolylhydrazide Inhibitors versus KDM4 Histone Demethylases.ChemMedChem · 2019Article
- Emerging roles of and therapeutic strategies targeting BRD4 in cancer.Cellular immunology · 2019Review
- Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.Cancer discovery · 2017Article
- Maintenance of macrophage transcriptional programs and intestinal homeostasis by epigenetic reader SP140.Science immunology · 2017Article
- EZH2 as a mediator of treatment resistance in melanoma.Pigment cell & melanoma research · 2016Review
- Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches.Frontiers in immunology · 2016Review
- Transcriptional Activation of Inflammatory Genes: Mechanistic Insight into Selectivity and Diversity.Biomolecules · 2015Review
- Loss of EZH2 results in precocious mammary gland development and activation of STAT5-dependent genes.Nucleic acids research · 2015Article
- Disruption of crosstalk between mesenchymal stromal and tumor cells in bone marrow as a therapeutic target to prevent metastatic bone disease.Journal of cellular physiology · 2014Article
- Preparing the first responders: building the inflammatory transcriptome from the ground up.Molecular cell · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in the enzymology of transcription and chromatin regulation have led to the discovery of proteins that play a prominent role in cell differentiation and the maintenance of specialized cell functions. Knowledge about post-synthetic DNA and histone modifications as well as information about the rules that guide the formation of multimolecular chromatin-bound complexes have helped to delineate gene-regulating pathways and describe how these pathways are altered in various pathological conditions. The present review focuses on the emerging area of therapeutic interference with chromatin function for the purpose of cancer treatment and immunomodulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.